Tumor-associated antigens from autologous malignant glioma lysate (AGL)

Tumor-associated antigens from autologous malignant glioma lysate represent a personalized collection of proteins and peptides derived directly from a patient's own surgically resected tumor tissue. This lysate contains a broad spectrum of both known and unidentified antigens, including neoantigens resulting from somatic mutations unique to the individual's cancer (Liau et al., 2023). In a therapeutic context, these antigens are typically loaded onto autologous dendritic cells to prime the immune system to recognize and attack glioma cells (NCI Drug Dictionary). By using the full lysate rather than single synthetic peptides, the approach aims to overcome the high degree of intratumoral heterogeneity and prevent antigen escape, where the tumor evolves to stop expressing a single targeted protein (PubMed: 30107140). This strategy is primarily investigated for the treatment of glioblastoma multiforme (GBM), where it seeks to induce a robust, polyclonal cytotoxic T-lymphocyte response (Polyzoidis & Ashkan, 2014). The use of autologous material ensures that the therapy is tailored to the specific antigenic profile of the patient's unique malignancy.

Other names

Autologous tumor lysateGlioma-associated antigensPatient-specific tumor antigensAutologous glioma lysate

The lysate serves as a source of multiple tumor-associated antigens that are processed and presented by dendritic cells to activate a polyclonal T-cell-mediated immune response against the tumor.